Isolation of anxiolytic principle from ethanolic root extract of Cardiospermum halicacabum

Phytomedicine

Volumn 18, Issue 2-3, 2011, Pages 219-223

  Kumar, Rajesh ^a   Murugananthan, G ^a   Nandakumar, K ^b   Talwar, Sahil ^b  

^a PES COLLEGE OF PHARMACY   (India)

^b MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Anxiolytic effect; Cardiospermin; Cardiospermum halicacabum; Elevated plus maze test; Light dark model

Indexed keywords

ALCOHOL; CARDIOSPERNUM HALICACABUM EXTRACT; GUM ARABIC; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG ISOLATION; DRUG MECHANISM; LIGHT DARK CYCLE; MAZE TEST; MOUSE; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; REARING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DIAZEPAM; DISEASE MODELS, ANIMAL; GLUCOSIDES; LIGHT; MALE; MAZE LEARNING; MICE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; SAPINDACEAE;

ACACIA; CARDIOSPERMUM HALICACABUM; MUS;

EID: 78651314855     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2010.07.002     Document Type: Article

References (24)

1. G. Beaubrum, and G.E. Gray A review of herbal medicines for psychiatric disorder Psychiatr. Serv. 51 2000 1130 1134
2. C. Belzung, R. Misslin, E. Vogel, R.H. Dodd, and G. Chapouthier Anxiogenic effects of methyl-h carboline-carboxylate in a light/dark choice situation Pharmacol. Biochem. Behav. 28 1987 29 33
3. B. Costall, B.J. Jones, M.E. Kelly, R.J. Naylor, and D.M. Tomkins Exploration of mice in a black and white test box: validation as a model of anxiety Pharmacol. Biochem. Behav. 32 1989 777 785
4. J.N. Crawley, and F.K. Goodwin Preliminary report of a simple animal behaviour for the anxiolytic effects of benzodiazepines Pharmacol. Biochem. Behav. 13 1980 167 170
5. J. Eguchi, Y. Inomata, and K.I. Saito The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism Pharmacol. Biochem. Behav. 68 2001 677 683
6. P.E. Greenberg, T. Sisitsky, R.C. Kessler, S.N. Finkelstein, E.R. Berndt, and J.R.T. Davidson The economic burden of anxiety disorders in the 1990s J. Clin. Psychiatry 60 1999 427 435
7. D.R. Helton, J.E. Berger, J.F. Czachura, K. Rasmussen, and M.J. Kallman Central nervous system characterization of new cholecystokinin B antagonist LY288513 Pharmacol. Biochem. Behav. 53 1996 493 502
8. W. Hubel, and A. Nahrstedt Cardiosperminsulfate - a sulphur containing cyanogenic glucoside from Cardiospermum grandiflorum Tetrahedron Lett. 20 1979 4395 4396
9. A.D. Jordan, C.P. Kordik, A.B. Reitz, and P.J. Sanfillipo Novel anxiolytic agents-1994-to present Expert Opin. Ther. Pat. 6 1996 1047 1060
10. M. Lader, and S. Morton Benzodiazepine problems Br. J. Addict. 86 1991 823 828
11. E.M. Lepicard, C. Joubert, I. Hagneau, F. Perez-Diza, and G. Chapouthier Differences in anxiety-related behavior and response to diazepam in BALB/cByJ and C57BL/6J strains of mice Pharmacol. Biochem. Behav. 67 2000 739 748
12. R.G. Lister The use of a plus-maze to measure anxiety in the mouse Psychopharmacology 92 1987 180 185
13. P.C. Moser An evaluation of the elevated plus-maze using the novel anxiolytic buspirone Psychopharmacology 99 1989 48 53
14. C. Muthu, M. Ayyanar, N. Raja, and S. Ignacimuthu Medicinal plants used by traditional healers in Kancheepuram District of Tamil Nadu, India J. Ethnobiol. Ethnomed. 2 2006 43 46
15. S. Pellow, P. Chopin, S.E. File, and M. Briley Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J. Neurosci. Methods 14 1985 149 167
16. S. Pellow, and S.E. File Anxiolytic and anxiogenic drug effect on exploratory activity in elevated plus maze: a novel test of anxiety in rats Pharmacol. Biochem. Behav. 24 1986 524 529
17. A. Rex, E. Morgenstern, and H. Fink Anxiolytic-like effects of Kava-Kava in the elevated plus maze test - a comparison with diazepam Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 855 860
18. D.P. Rice, and L.S. Miller Health economics and cost implications of anxiety and other mental disorders in the United States Br. J. Psychiatry 173 1998 4 9
19. K. Rickels, and E. Schweizer The clinical presentation of generalized anxiety in primarycare setting: practical concepts of classification and management J. Clin. Psychiatry 58 1997 4 9
20. R.J. Rodgers, and N.J.T. Johnson Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze Pharmacol. Biochem. Behav. 52 1995 297 303
21. J.J. Seo, S.H. Lee, Y.S. Lee, B.M. Kwon, Y. Ma, and B.Y. Hwang Anxiolytic-like effects of obovatol isolated from Magnolia obovata: Involvement of GABA/benzodiazepine receptors complex Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 1363 1369
22. K.C. Venkteshbabu, and S. Krishnakumari Cardiospermum halicacabum suppress the production of TNF-alpha nitric oxide by human peripheral blood mononuclear cells Afr. J. Biomed. Res. 9 2006 95 99
23. H.U. Wittchen, and J. Hoyer Generalized anxiety disorder: nature and course J. Clin. Psychiatry 62 2001 15 21 (Pubitemid 32537573)
24. R. Young, and D.N. Johnson A fully automated light/dark apparatus useful for comparing anxiolytic agents Pharmacol. Biochem. Behav. 40 1991 739 743